1,834 results on '"Radich, Jerald"'
Search Results
2. Point-of-care BCR::ABL1 transcript monitoring using capillary dried blood in chronic myeloid leukemia patients
3. Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation at a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional study
4. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
5. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
6. Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients
7. Management of chronic myeloid leukemia in 2023 – common ground and common sense
8. CRISPR-based rapid molecular diagnostic tests for fusion-driven leukemias
9. CML Outcomes and Care Delivery During the COVID-19 Pandemic in Low- and Middle-Income Countries
10. Ultrasensitive chimerism enhances measurable residual disease testing after allogeneic hematopoietic cell transplantation
11. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
12. Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021
13. Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies
14. qPCR assay for detection of Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Elements from CAR-T and TCR-T cells in fresh and formalin-fixed tissue
15. BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis
16. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts
17. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia
18. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
19. AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker
20. MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis
21. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms
22. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
23. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.
24. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.
25. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
26. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation
27. CML and the WHO: Why?
28. Chronic Myeloid Leukemia: Chronic Phase Disease
29. Hematopoietic Cell Transplantation in Chronic Myeloid Leukemia
30. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
31. 4. Comprehensive next generation cytogenomics improves risk stratification of acute myeloid leukemia
32. Analysis of the gap in PCR monitoring availability for patients with chronic myeloid leukemia in 60 low- and middle-income countries
33. A graphical, interactive and GPU-enabled workflow to process long-read sequencing data
34. New approaches to molecular monitoring in CML (and other diseases)
35. Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
36. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
37. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients
38. Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies
39. Rapid detection of myeloid neoplasm fusions using single-molecule long-read sequencing
40. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia
41. The (near) miracle of therapy in chronic myeloid leukaemia
42. Ultrasensitive Chimerism Enhances Measurable Residual Disease Testing Post-Allogeneic Hematopoietic Cell Transplantation
43. Chronic Myelogenous Leukemia, Version 1.2014.
44. Point-of-care BCR::ABL1transcript monitoring using capillary dried blood in chronic myeloid leukemia patients
45. Monitoring efforts in myeloproliferative neoplasms
46. Minimal Residual Disease
47. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies
48. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms
49. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop.
50. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.